DBD vs MSFT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DBD presents a stark dichotomy between explosive earnings growth and concerning sentiment indicators. With a Piotroski F-Score of 4/9, the company's financial health is categorized as stable but lacks strong momentum. While the stock currently trades at a premium to its Graham Number ($42.15) and Intrinsic Value ($74.93), the low forward P/E of 12.75 suggests the market is pricing in continued earnings acceleration. However, heavy insider liquidation and a bearish technical trend significantly offset the strong analyst 'strong_buy' consensus.
Microsoft exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust financial stability. While the stock is currently experiencing a severe technical downtrend (0/100) and significant 6-month price depreciation (-28.6%), the current price of $374.33 sits well below the growth-based intrinsic value of $471.41 and the analyst target of $587.31. Exceptional earnings growth (59.8% YoY) and high operating margins (47.09%) suggest that the current price correction presents a value opportunity despite bearish insider sentiment.
Compare Another Pair
Related Comparisons
DBD vs MSFT: Head-to-Head Comparison
This page compares Diebold Nixdorf, Incorporated (DBD) and Microsoft Corporation (MSFT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.